pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
367
stories
27d
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
stat
28d
STAT+: Up and down the ladder: The latest comings and goings
stat
28d
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
stat
28d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
28d
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
28d
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
stat
28d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
28d
STAT+: European regulators take steps to bolster clinical trial transparency
stat
29d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
29d
FDA panel confronting peptide controversy
stat
29d
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
29d
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
29d
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
29d
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
29d
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
29d
Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
endpoints
29d
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
stat
29d
Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near
endpoints
29d
Opinion: New billing codes likely to raise maternity care costs
stat
29d
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
29d
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
STAT+: Pharma tries to tamp down broad China restrictions
stat
Jul 21, 26
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
endpoints
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
Jul 21, 26
Is there an exodus underway at Epic?
stat
Jul 21, 26
STAT+: Anthropic deepens work with rare disease drugs
stat
Jul 21, 26
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
Jul 21, 26
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
stat
Jul 21, 26
Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs
biospace
← prev
page 4 of 13
next →
